A mouse/human chimeric monoclonal antibody (mAb) composed of the variable regions of
murine 17-1A mAb and the constant regions of human IgG-1K immunoglobulin was …

PURPOSE: To evaluate the safety, pharmacokinetics, and efficacy of a chimeric anti–epidermal
growth factor receptor monoclonal antibody, cetuximab, in combination with radiation …

Background. Our objectives were to determine the incidence of acute and late toxicities and
to estimate the 2‐year overall survival for patients treated with reirradiation and …

In a phase I trial, 12 patients with G D2 antigen-positive metastatic melanoma received the
murine anti-G D2 monoclonal antibody 14G2a. The monoclonal antibody was administered in …

The chimeric monoclonal anti-GD2 antibody ch14. 18 is made up of the variable region of
the murine anti-GD2 antibody 14.18 (or its IgG2a switch variant 14G2a) and the constant …

Background Monoclonal antibodies (mAb) to epidermal growth factor receptor (EGFr) inhibit
tumor cell proliferation and enhance cytotoxicity of chemotherapeutic agents. The purpose …

MATERIALS AND METhODS Clinical Protocol Eligible patients had histologically confirmed
adenocarcinoma of the prostate and had failed standardhormonaltherapy. Eligi biity …

Chimeric B72.3, composed of the V-regions of murine B72.3 and the constant regions of
human immunoglobulin G4 heavy and κ light chain, was administered as a 131 I-labeled …

The combination of COL-1 (anti-CEA) and CC49 (anti-TAG-72) has shown an increase in
binding and distribution in colon cancer by immunoperoxidase staining compared to either …

Twenty-five patients with metastatic gastrointestinal adenocarcinoma received one to four
infusions of large doses (400 mg) of murine monoclonal antibody CO17-1A (17-1A). The …